A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

NCT00002222 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Retinitis
HIV Infections

Interventions

DRUG: Valganciclovir

Sponsor

Hoffmann-La Roche